Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED
Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
41 42 Next >
News headline image
Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved ↗
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami... 
Via Benzinga
News headline image
Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage ↗
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami... 
Via Benzinga
Three Kinds of Trauma Psychedelics Hope to Treat
Via Investor Brand Network
News headline image
Cybin Presents "Why Cybin Is Investing So Heavily On Developing Novel Psychedelic Molecules" At The Psychedelic Capital Conference ↗
Photo by Presetbase Lightroom Presets on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
News headline image
Field Trip Health, Mind Medicine Among Top Psychedelic Movers Of Today ↗
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 3.49% at $0.87 
Via Benzinga
News headline image
Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp ↗
Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to... 
Via Benzinga
News headline image
Cybin (NYSE American: CYBN) (NEO: CYBN) To Present At KCSA Psychedelics Conference ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at KCSA Psychedelics Virtual Investor Conference
Via Investor Brand Network
News headline image
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
From Cybin Inc.
Via Business Wire
News headline image
Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today ↗
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 20.83% at $0.29 
Via Benzinga
Volume of Gray Matter May Be Useful in Treatment Planning for Mental Health Conditions
Via Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment
Via Investor Brand Network
Roth Capital Reveals Top Psychedelic Picks in New Industry Report
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report... 
Via FinancialNewsMedia
News headline image
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
News headline image
Psychedelic Stock Gainers And Losers From April 20, 2022 ↗
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.69% at $0.16 LOSERS: 
Via Benzinga
News headline image
EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space ↗
Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock. In the psychedelic space, catalysts could be... 
Via Benzinga
News headline image
Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today ↗
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.57% at $0.33 
Via Benzinga
News headline image
EXCLUSIVE: How Cybin Is Developing The Next Generation Of Psychedelics ↗
If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you. 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Pipeline Program Receives Key Patent Approval
Via Investor Brand Network
Topics Intellectual Property
News headline image
Psychedelic Stock Gainers And Losers From April 18, 2022 ↗
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.66% at $0.28 
Via Benzinga
News headline image
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
News headline image
Psychedelic Stock Gainers And Losers From April 14, 2022 ↗
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 2.50% at $5.32 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
News headline image
Psychedelic Stock Gainers And Losers From April 13, 2022 ↗
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.41% at $0.24 
Via Benzinga
News headline image
Cybin's (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study
Via Investor Brand Network
News headline image
Cybin's CYB0004 Shows Positive Preclinical Results Over Traditional Psychedelics ↗
CYB004 is one of Cybin’s (NYSE: CYBN) proprietary second-generation psychedelics, developed to treat depression, anxiety, and ... 
Via Benzinga
Why Psychedelics Could Soon Replace Antidepressants
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults... 
Via FinancialNewsMedia
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.